Hotchkis & Wiley Capital Management LLC increased its position in shares of GlaxoSmithKline PLC (NYSE:GSK) by 4.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,847,327 shares of the pharmaceutical company’s stock after acquiring an additional 322,700 shares during the quarter. GlaxoSmithKline PLC comprises 1.4% of Hotchkis & Wiley Capital Management LLC’s holdings, making the stock its 26th biggest position. Hotchkis & Wiley Capital Management LLC owned 0.32% of GlaxoSmithKline PLC worth $338,377,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bronfman E.L. Rothschild L.P. raised its stake in shares of GlaxoSmithKline PLC by 45.4% during the 1st quarter. Bronfman E.L. Rothschild L.P. now owns 2,410 shares of the pharmaceutical company’s stock worth $102,000 after acquiring an additional 753 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its stake in shares of GlaxoSmithKline PLC by 1,747.4% during the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 2,494 shares of the pharmaceutical company’s stock worth $105,000 after acquiring an additional 2,359 shares in the last quarter. Proficio Capital Partners LLC raised its stake in shares of GlaxoSmithKline PLC by 233.0% during the 1st quarter. Proficio Capital Partners LLC now owns 2,844 shares of the pharmaceutical company’s stock worth $122,000 after acquiring an additional 1,990 shares in the last quarter. Heritage Trust Co bought a new position in shares of GlaxoSmithKline PLC during the 1st quarter worth approximately $123,000. Finally, Westwood Holdings Group Inc. raised its stake in shares of GlaxoSmithKline PLC by 15.7% during the 1st quarter. Westwood Holdings Group Inc. now owns 2,950 shares of the pharmaceutical company’s stock worth $124,000 after acquiring an additional 400 shares in the last quarter. Hedge funds and other institutional investors own 9.29% of the company’s stock.

Several research analysts recently commented on GSK shares. TheStreet upgraded shares of GlaxoSmithKline PLC from a “c” rating to a “b” rating in a research note on Friday, May 19th. Berenberg Bank upgraded shares of GlaxoSmithKline PLC from a “hold” rating to a “buy” rating in a research note on Friday, May 26th. J P Morgan Chase & Co reiterated a “neutral” rating on shares of GlaxoSmithKline PLC in a research note on Wednesday, May 31st. ValuEngine lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Citigroup Inc. lowered shares of GlaxoSmithKline PLC from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $46.00.

Shares of GlaxoSmithKline PLC (GSK) traded down 0.27% during mid-day trading on Friday, reaching $40.24. 3,006,781 shares of the company were exchanged. The stock has a market capitalization of $98.35 billion, a P/E ratio of 39.76 and a beta of 1.03. The stock has a 50 day moving average price of $39.80 and a 200-day moving average price of $41.77. GlaxoSmithKline PLC has a 12 month low of $37.20 and a 12 month high of $44.54.

GlaxoSmithKline PLC (NYSE:GSK) last issued its earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.68 by $0.02. The company had revenue of $9.36 billion for the quarter, compared to analyst estimates of $9.52 billion. GlaxoSmithKline PLC had a net margin of 6.48% and a return on equity of 114.93%. Analysts predict that GlaxoSmithKline PLC will post $2.87 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 12th. Shareholders of record on Friday, August 11th will be given a dividend of $0.491 per share. This is a positive change from GlaxoSmithKline PLC’s previous quarterly dividend of $0.46. This represents a $1.96 annualized dividend and a dividend yield of 4.88%. The ex-dividend date of this dividend is Wednesday, August 9th. GlaxoSmithKline PLC’s payout ratio is presently 197.00%.

TRADEMARK VIOLATION WARNING: “Hotchkis & Wiley Capital Management LLC Acquires 322,700 Shares of GlaxoSmithKline PLC (GSK)” was first reported by Daily Political and is owned by of Daily Political. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.dailypolitical.com/2017/09/16/hotchkis-wiley-capital-management-llc-acquires-322700-shares-of-glaxosmithkline-plc-gsk.html.

GlaxoSmithKline PLC Company Profile

GlaxoSmithKline plc is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases.

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline PLC and related companies with MarketBeat.com's FREE daily email newsletter.